Condition: Von Willebrand Disease (VWD) · Sponsor: Vega Therapeutics, Inc
This is a phase 3 study that will evaluate subcutaneous (SC) VGA039 in patients with von Willebrand Disease (VWD)
This description comes directly from the study's public registry record.
Clinical Trials- Vega Therapeutics · 650-466-8041 · medinfo@star-therapeutics.com
Always discuss trial participation with your own doctor first.
| Arkansas Children's Hospital | Little Rock, Arkansas, United States | Recruiting |
| Luskin Orthopaedic Institute For Children | Los Angeles, California, United States | Recruiting |
| UC Davis Medical Center | Sacramento, California, United States | Recruiting |
| University of California San Francisco | San Francisco, California, United States | Recruiting |
| Emory University Hospital | Atlanta, Georgia, United States | Recruiting |
| Children's Healthcare of Atlanta | Atlanta, Georgia, United States | Recruiting |
| University of Minnesota | Minneapolis, Minnesota, United States | Recruiting |
| Science 37, Inc. (Virtual Clinical MetaSite) | Morrisville, North Carolina, United States | Recruiting |
| Hemophilia Center of Western PA | Pittsburgh, Pennsylvania, United States | Recruiting |
| UT Southwestern Children's Hospital | Dallas, Texas, United States | Recruiting |
| Washington Center for Bleeding Disorders | Seattle, Washington, United States | Recruiting |
| K Eristavi National Center of Experimental and Clinical Surgery (ქირურგიის ეროვნული ცენტრი) | Tbilisi, Georgia | Recruiting |
+ 2 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07115004